Evidence map›Paper›PMID 26493458›Full record

Observational studyBMJ open2015

Patients who discontinued statin treatment: a protocol for cohort study using primary care data.

Yana Vinogradova, Carol Coupland, Peter Brindle, Julia Hippisley-Cox

Open access · goldFull text readObservational Study
In one paragraph

Observational study in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Nutraceuticals in hypercholesterolaemia: an overview.British journal of pharmacology · 2017
    Review
  4. Discontinuation of Statins: What Are the Risks?Current atherosclerosis reports · 2016
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yana VinogradovaDivision of Primary Care, University of Nottingham, Nottingham, UK.
Carol CouplandDivision of Primary Care, University of Nottingham, Nottingham, UK.
Peter BrindleBristol Clinical Commissioning Group, Bristol, UK.
Julia Hippisley-CoxDivision of Primary Care, University of Nottingham, Nottingham, UK.
University of Nottingham · GBBristol Clinical Commissioning Group · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRisk thresholds for using statins to prevent cardiovascular disease (CVD) have recently been lowered, so an increasing number of patients are now prescribed these drugs. Although the safety of long-term statin use has been generally established, concerns about the balance of risks and benefits of statins still exist for some medical professionals and patients, and issues concerning their side effects are occasionally widely publicised. This study will report the rates of stopping for statins and also identify any patient groups more likely to stop using statins, so possibly increasing their risk of cardiovascular events. METHODS AND ANALYSIS: A prospective open cohort study between 1 January 2002 and 30 September 2014 will be based on the general population of people prescribed statins, using records from UK general practices contributing to the Clinical Practice Research Database (CPRD). Participants aged 25-84 years will enter the cohort on the date of their first prescription for a statin and leave on the earliest date of: a cardiovascular event; death; leaving the practice; the last practice upload date or the study end date. If there are no prescriptions within 90 days after the expected finishing date of a prescription, a patient will be defined as a stopper with the discontinuation outcome date as the expected finishing date. Rates of statin discontinuation will be calculated by calendar year, type and dose of statin, age, and morbidities. Cox proportional regression analyses will be run to identify the most important factors associated with discontinuation. Analyses will be run separately for patients without CVD (primary prevention) and with diagnosed CVD (secondary prevention). ETHICS AND DISSEMINATION: The protocol has been reviewed and approved by Independent Scientific Advisory Committee for MHRA Database Research. The results will be published in a peer-reviewed journal.

Indexed as

Clinical ProtocolsResearch DesignAdultAgedAged, 80 and overCardiovascular DiseasesDatabases, FactualFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedNonprescription DrugsPrimary Health CarePrimary PreventionProspective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsNonprescription Drugscardiovascular diseasediscontinuationstatins

Identifiers

PMID26493458
PMCPMC4620169
OpenAlexW2175684233

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.